Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica
Executive Summary
With a monthly cost of $10,900/month for the ultra-rare disease mantle cell lymphoma, Pharmacyclics and Janssen are being proactive about patient aid with a 30-day offer while reimbursement is worked out, as well as other support offerings that have become part of the new reality for high-priced oncologics.
You may also be interested in...
Free Imbruvica Program Cleared By HHS Inspector General
An advisory opinion says a program sponsored by Johnson & Johnson and AbbVie to provide up to 60 days of the cancer drug Imbruvica for free to patients who experience delays in receiving insurance coverage approval is at low risk of raising anti-kickback concerns.
Deal Watch: AstraZeneca Buys, Sells And Partners In Busy Week
In frenetic week, AstraZeneca signs PD-L1 combo study pact, buys data-analysis firm and divests generalized lipodystrophy drug to Aegerion to focus pipeline efforts on core areas. Merck becomes the latest big pharma to sign on with Bind, and Astellas and Proteostasis agree to an R&D collaboration in unfolded protein response.
CLL Market Snapshot: Seismic Changes Rock The Treatment Landscape
The market for chronic lymphocytic leukemia drugs is undergoing big changes, with three new drugs approved: Roche’s antibody Gazyva and two oral therapies from Pharmacyclics/J&J and Gilead. Side effect profiles, administration and progression-free survival rates are helping to guide treatment decisions.